Scientific Sessions 2025  /  TCT at AHA: Heart Team in Action: Arrhythmogenic Mitral Valve Prolapse: Predicting Risk, Protecting Patients, and Personalizing Treatment  /  Defining the Role of Ablation Therapies and ICD in Arrythmic Mitral Valve Prolapse
Logo

American Heart Association

  77
  0

Final ID:

Defining the Role of Ablation Therapies and ICD in Arrythmic Mitral Valve Prolapse

  • Miller, Marc  ( Mount Sinai Hospital , New York , New York , United States )
  • Sabbag, Avi  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Delling, Francesca  ( UCSF , San Francisco , California , United States )
    • Author Disclosures:
    Marc Miller: DO NOT have relevant financial relationships | Avi Sabbag: No Answer | Francesca Delling: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

TCT at AHA: Heart Team in Action: Arrhythmogenic Mitral Valve Prolapse: Predicting Risk, Protecting Patients, and Personalizing Treatment

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Current Strategies for Medical Treatment of Arrythmogenic Mitral Valve Prolapse

Tribouilloy Christophe, Enriquez-sarano Maurice, Michelena Hector

Mitral Valve Surgery in Arrhythmogenic Mitral Regurgitation: Special Considerations

Borger Michael, Adams David, Gillinov A Marc, Nguyen Tom, Ramzy Danny

More abstracts from these authors:
Atrial Fibrillation in Valvular Heart Disease: Assessing the Impact of Genetics in the UK Biobank

Cristin Luca, Tang Janet, Tastet Lionel, Marcus Gregory, Delling Francesca

Cardiovascular AI based Imaging and the End user experience

Leiner Tim, Delling Francesca, Zareba Karolina, Wiens Jenna

You have to be authorized to contact abstract author. Please, Login
Not Available